RTI Surgical® Announces First Spine Surgery Using the HPS™ 2.0 Hybrid Performance System
September 17 2019 - 04:30PM
RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical
implant company, today announced the first surgery using the HPS™
2.0 Hybrid Performance System, a modular pedicle screw system used
for mono- and multi-segmental rigid, hybrid or dynamic posterior
stabilization of the thoracolumbar spine. Dr. William Sears, a
neurosurgeon and Fellow of the Royal Australasian College of
Surgeons, performed the surgery at Sydney Adventist Hospital in
Sydney, Australia.
The rigidity of segments treated with spinal
fusion surgery can result in abnormal, increased loads on adjacent,
untreated segments, which can lead to adjacent segment degeneration
(ASD) and cause new symptoms. The HPS 2.0 Hybrid Performance System
offers an alternative to conventional, rigid implant systems by
providing the option of dynamically stabilizing one or more
segments adjoining a fusion, which may reduce the length of the
fusion while preserving motion, help to alleviate pain and reduce
the risk of ASD.i
“I have been pleased with my experiences using
the HPS Hybrid Performance System to decrease the risk of adjacent
segment degeneration, alleviate pain and improve outcomes for my
patients,” said Dr. Sears. “I’m excited about the major
improvements the HPS 2.0 system brings, and I look forward to
working with RTI to develop more clinical data supporting its
effectiveness.”
The HPS 2.0 Hybrid Performance System features
significant updates to the HPS system’s clinically proven DSS®
coupler technology, which enables restoration of segmental
stability while preserving motion and reducing the mechanical
burden on adjacent segments. Other improvements to the HPS 2.0
system include the ability to use couplers at multiple segments and
substantial enhancements to the screw shank, head design and
coupler and rod inserters.ii
“Surgeons and patients have experienced
firsthand the benefits of the HPS Hybrid Performance System, with
more than 30,000 patients treated over the past 10 years. We are
pleased to introduce the next evolution of this treatment option
with the HPS 2.0 system,” said Camille Farhat, President and CEO,
RTI Surgical. “The HPS Hybrid Performance System is one of the few
technologies in this category supported by data and with a track
record of solid clinical outcomes for posterior dynamic
stabilization patients. Further, in choosing the HPS system,
surgeons can potentially help prevent the onset of ASD in these
patients. Generating more data on this important condition will be
a critical part of our efforts to drive product innovation within
our increasingly differentiated spine portfolio and treat more
patients.”
The HPS 2.0 Hybrid Performance System is
currently under limited market release in Australia and Europe in
preparation for a full commercial launch in Australia, Europe and
Taiwan. The HPS Hybrid Performance System and HPS 2.0 Hybrid
Performance System are not available in the United States.
About RTI Surgical Holdings,
Inc.
RTI Surgical Holdings, Inc. is a leading
global surgical implant company providing surgeons with safe
biologic, metal and synthetic implants. Committed to delivering a
higher standard, RTI’s implants are used in sports medicine,
general surgery, spine, orthopedic and trauma procedures and are
distributed in nearly 50 countries. RTI has four manufacturing
facilities throughout the U.S. and Europe. RTI is accredited in the
U.S. by the American Association of Tissue Banks and is a member of
AdvaMed. For more information, please visit www.rtix.com.
Connect with us on LinkedIn and Twitter.
Forward-Looking StatementsThis
communication contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on management’s current
expectations, estimates and projections about our industry, our
management's beliefs and certain assumptions made by our
management. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," variations of such words
and similar expressions are intended to identify such
forward-looking statements. In addition, except for historical
information, any statements made in this communication about
anticipated financial results, growth rates, new product
introductions, future operational improvements, gaining market
share and results or regulatory actions or approvals or changes to
agreements with distributors also are forward-looking statements.
These statements are not guarantees of future performance and are
subject to risks and uncertainties, including the risks described
in public filings with the U.S. Securities and Exchange Commission
(SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements.
Copies of the company's SEC filings may be obtained by contacting
the company or the SEC or by visiting RTI's website at
www.rtix.com or the SEC's website at www.sec.gov.
Molly PoarchInvestor
Contactmpoarch@rtix.com+1 224 287 2661
Andrea JohnsonMedia
Contactamjohnson@rtix.com+1 630 518 5345
i Data on file at RTI Surgical Holdings,
Inc.
ii Data on file at RTI Surgical Holdings,
Inc.
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Mar 2023 to Mar 2024